BCLI
Price
$0.98
Change
+$0.06 (+6.52%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
5.65M
XTLB
Price
$1.46
Change
+$0.16 (+12.31%)
Updated
Apr 25, 04:50 PM (EDT)
Capitalization
10.95M
Ad is loading...

BCLI vs XTLB

Header iconBCLI vs XTLB Comparison
Open Charts BCLI vs XTLBBanner chart's image
Brainstorm Cell Therapeutics
Price$0.98
Change+$0.06 (+6.52%)
Volume$200
Capitalization5.65M
XTL Biopharmaceuticals
Price$1.46
Change+$0.16 (+12.31%)
Volume$125
Capitalization10.95M
BCLI vs XTLB Comparison Chart
Loading...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCLI vs. XTLB commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCLI is a Hold and XTLB is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (BCLI: $0.92 vs. XTLB: $1.30)
Brand notoriety: BCLI and XTLB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCLI: 35% vs. XTLB: 14%
Market capitalization -- BCLI: $5.65M vs. XTLB: $10.95M
BCLI [@Biotechnology] is valued at $5.65M. XTLB’s [@Biotechnology] market capitalization is $10.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCLI’s FA Score shows that 0 FA rating(s) are green whileXTLB’s FA Score has 0 green FA rating(s).

  • BCLI’s FA Score: 0 green, 5 red.
  • XTLB’s FA Score: 0 green, 5 red.
According to our system of comparison, XTLB is a better buy in the long-term than BCLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCLI’s TA Score shows that 5 TA indicator(s) are bullish.

  • BCLI’s TA Score: 5 bullish, 3 bearish.

Price Growth

BCLI (@Biotechnology) experienced а +5.02% price change this week, while XTLB (@Biotechnology) price change was +15.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.

Reported Earning Dates

BCLI is expected to report earnings on Mar 31, 2025.

XTLB is expected to report earnings on Dec 03, 2024.

Industries' Descriptions

@Biotechnology (+7.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XTLB($11M) has a higher market cap than BCLI($5.65M). XTLB YTD gains are higher at: -35.828 vs. BCLI (-59.471). XTLB has higher annual earnings (EBITDA): 630K vs. BCLI (-13.06M). BCLI has more cash in the bank: 168K vs. XTLB (133K). BCLI (0) and XTLB (0) have equivalent revenues.
BCLIXTLBBCLI / XTLB
Capitalization5.65M11M51%
EBITDA-13.06M630K-2,072%
Gain YTD-59.471-35.828166%
P/E RatioN/AN/A-
Revenue00-
Total Cash168K133K126%
Total Debt841KN/A-
FUNDAMENTALS RATINGS
BCLI vs XTLB: Fundamental Ratings
BCLI
XTLB
OUTLOOK RATING
1..100
12
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
9664
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XTLB's Valuation (52) in the Biotechnology industry is somewhat better than the same rating for BCLI (89) in the Computer Peripherals industry. This means that XTLB’s stock grew somewhat faster than BCLI’s over the last 12 months.

XTLB's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

XTLB's SMR Rating (92) in the Biotechnology industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

XTLB's Price Growth Rating (64) in the Biotechnology industry is in the same range as BCLI (96) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

XTLB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCLI
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 5 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 15 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TMCJX44.80N/A
N/A
Touchstone Mid Cap C
GHAIX39.74N/A
N/A
VanEck Global Resources Fund I
FSYNX8.94N/A
N/A
Fidelity Advisor Sustainable EM Eq M
EACPX51.97N/A
N/A
Eaton Vance Tax-Managed Multi-Cap Gr A
EKBDX12.08N/A
N/A
Allspring Diversified Cap Bldr Adm

BCLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCLI has been loosely correlated with VBIZF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCLI jumps, then VBIZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
+5.75%
VBIZF - BCLI
35%
Loosely correlated
N/A
ATHE - BCLI
35%
Loosely correlated
+0.85%
BLRX - BCLI
30%
Poorly correlated
+0.07%
XTLB - BCLI
29%
Poorly correlated
+7.00%
EYPT - BCLI
28%
Poorly correlated
-2.53%
More

XTLB and

Correlation & Price change

A.I.dvisor indicates that over the last year, XTLB has been loosely correlated with SER. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XTLB jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTLB
1D Price
Change %
XTLB100%
+7.00%
SER - XTLB
59%
Loosely correlated
+5.36%
BCLI - XTLB
27%
Poorly correlated
+5.75%
ADTX - XTLB
27%
Poorly correlated
-0.43%
ANRO - XTLB
27%
Poorly correlated
+0.44%
BCRX - XTLB
25%
Poorly correlated
+3.27%
More